Meanwhile, anti-cytokine therapies, such as infliximab, which blocks tumor necrosis factor (TNF), or siltuximab, which targets IL-6, intervene in tumor progression by inhibiting pro-tumorigenic cytokines [10,11]. The gene discussed is IL6; the disease is neoplasm.